Maureen Cavanaugh joined Lannett as senior vice president and chief commercial operations officer in 2018. Maureen is responsible for overseeing operations including sales and marketing, research and development (R&D) and regulatory affairs. With nearly 30 years of pharmaceutical industry experience, Maureen’s expertise includes new product launch planning and execution, strategic product management, identifying portfolio opportunities, and other critical operational functions.
Prior to joining Lannett, Maureen was the senior vice president, chief commercial officer, North America Generics, at Teva Pharmaceuticals USA. Prior to that, Maureen held a variety of senior positions in other leading companies in the pharmaceutical industry, including PAR, Sandoz, and Bristol Myers-Squibb. Maureen earned her Bachelor of Science degree in Business Administration at LaSalle University and her Master of Business Administration degree from Rider University.
Alicia Evolga joined Lannett as vice president of marketing in 2018. A savvy strategist, she has broad-based marketing expertise, deep customer relationships and an impressive track record on strategy, product and portfolio management including new product launches, cross-functional team management, and revenue growth in the generic pharmaceutical industry.
“We are building a marketing plan and organization to prioritize growth and uncover niche opportunities for our company. We want to highlight the strengths that differentiate us in the market: our agility, our community involvement, and our commitment to the generic pharmaceutical industry.”
Most recently, Alicia served as vice president of marketing for Cipla USA, where she built the marketing department from the ground up, leading all facets of marketing for the company’s US business. Previously, Alicia held roles of increasing responsibility at some of the largest generic pharmaceutical companies in the US, including Cipla USA, Lupin Pharmaceuticals, Apotex Corporation, and Impax Laboratories.
Alicia earned her Bachelor of Arts degree in International Affairs from the Florida State University.
Grant Brock joined Lannett Company in 2018. Prior to joining the company, he held various senior roles in operations and engineering at Aprecia Pharmaceuticals, Custom Powder Systems and Teva Pharmaceuticals. Dedicated to building a culture of operational excellence and continuous improvement, Grant brings a diverse set of experiences to Lannett, including operations, engineering, company acquisitions and integration, and helping facilities achieve FDA approvals for both facilities and products.
“In my career, the most rewarding achievements I have experienced have been associated within a team environment. In order to succeed in our industry, we need to develop the mindset of building and improving on what we did yesterday. Getting better at what we do every day needs to become part of who we are not just words we say. From an operational perspective in my opinion, creating a culture of continuous improvement only happens when every person knows that they have the ability to make a positive difference in our organization, every day. ”
Grant is a graduate of Xavier University’s PMP (Project Management Professional) program, Ohio State University’s Six Sigma Black Belt Certification program, and Cincinnati State Community College. Grant is an ISPE (CPIP) Certified Pharmaceutical Industry Professional.
Kristie Stephens joined Lannett Company in 1999 and was appointed vice president of regulatory affairs in 2016. Under her leadership, the regulatory affairs department has been instrumental in obtaining faster ANDA (Abbreviated New Drug Application) approvals and implementing internal electronic systems to fully comply with FDA submission requirements. The department services many different internal and external stakeholders with comprehensive, integrated systems and solutions and recently filed Lannett’s first NDA (New Drug Application) with full clinical studies.
“Lannett has a long history of achieving regulatory approvals and maintaining regulatory compliance. We are focused on submitting high quality applications to ensure patient access to safe, reliable medications as quickly as possible. We remain at the forefront of the organization for monitoring new and updated regulatory requirements and trends that will have an impact on our business.”
Kristie earned her Bachelor of Science degree in biology at Millersville University of Pennsylvania and earned her Master of Science degree in quality assurance/regulatory affairs at Temple University.
Kristin Arnold joined Lannett Company as vice president of research and development in 2017. In this role, she leads the R&D effort for new internally developed products focusing on generic and specialty finished products, and provides scientific input for third party projects. Kristin came to the company with strong technical expertise in pharmaceutical development and regulatory knowledge spanning 20 years of generic and specialty pharmaceutical product development and launch experience with companies such as Alvogen, URL/Mutual, and Alpharma (now Teva).
“Growth can present challenges, as we move from acquiring companies to becoming a multi-site entity with aligned objectives and common goals. Working through significant change throughout the organization, we are building the infrastructure to integrate people, systems, and technology for continued future expansion.”
An accomplished scientist, Kristin is a member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists, with 21 scientific publications and 8 US patents. Kristin holds a PhD in physical organic chemistry from the University of Miami.
Robert Ehlinger joined the company in July 2006 as chief information officer. In June 2011, he was promoted to vice president of logistics and chief information officer. Over his tenure, Bob has played a central role in leveraging technology to drive improvements throughout the organization. Following a major acquisition in 2015, he oversaw a two-year project to integrate and harmonize business processes for a consistent, streamlined platform across all plants. Under his leadership in IT, Lannett received a CIO 100 award in 2017 for distinguished work on automated testing tools and solutions.
“Technology is a differentiator. It has the power to change and advance how business is done–not only in the pharmaceutical industry, but across the board. Using technology helps our company reduce costs and drive innovation, so we can bring products to market faster.”
Prior to joining Lannett, Bob was the vice president of information technology at MedQuist, Inc., a healthcare services provider. Over his 10-year career at MedQuist, he held a number of operational and technology positions of increasing responsibility. Prior to MedQuist, he was the corporate director of information technology supporting acute care and ambulatory care health information systems and biomedical support services at Kennedy Health Systems (now Jefferson Health). Bob earned a Bachelor of Arts degree in physics from Gettysburg College in Gettysburg, PA.
John M. Abt joined Lannett Company as vice president of quality in 2015. Prior to joining Lannett, John served as vice president of global quality strategy at Teva Pharmaceuticals, where he oversaw the development and implementation of global quality operating plans, standardization and efficiency programs, and offshoring efforts, after taking on a number of quality and operations positions of increasing responsibility in the company.
“Quality is an attribute and a mindset that everyone in the organization must embrace. It’s one leg of a three legged stool. The other two legs are cost and customer service; we can’t successfully run our business without all three. Our role is not to police the organization or confirm quality simply by testing the product before it goes out the door. Our role is to establish the policies and systems that enable every employee to do their job in a compliant and effective manner, so we consistently deliver products and services that are right the first time. We do this by eliminating non-value added activities: the highest quality processes are fast, inexpensive, and simple.”
John earned a Doctorate of Business Administration from Temple University, a Master of Administrative Sciences degree in management from Johns Hopkins University, and a Bachelor of Science degree in biochemistry from Niagara University.
John Kozlowski joined Lannett Company in 2009. During his tenure at the company, John has held a number of senior level finance positions, including corporate controller and vice president financial operations. In 2017, John was promoted to chief operating officer. In this role, he was responsible for strategic planning and primary business operations, including production, R&D, business development, marketing, supply chain, regulatory, and quality. In 2019, John was promoted to vice president of finance and chief financial officer.
“In matters of corporate finance and operations, it’s critical to focus on strategic planning as you develop teams and systems. We’re always working to improve our operations processes to foster ownership, accountability, and alignment with the core values of our company.”
Prior to joining the company, John served in senior finance and accounting roles for Optium Corporation and Finisar Australia. He earned his Bachelor of Arts degree in finance from James Madison University and a Master of Business Administration degree from Rider University.
Samuel H. Israel was appointed vice president, chief legal officer, and general counsel in July 2017. Prior to joining Lannett, he was a partner with Fox Rothschild, a national, full-service law firm, with 22 offices providing legal services in more than 60 practice areas. He served as chair of the firm’s Pharmaceutical and Biotechnology practice and handled a variety of commercial litigation matters.
“Our role is to provide sound legal advice and mitigate risk within a heavily regulated industry. To that end, we have led initiatives for an even stronger, more comprehensive system of compliance across a whole range of areas. We want to maintain Lannett’s excellent track record of reliability, bringing quality products to market while keeping our customers safe.”
Sam earned a Bachelor of Science degree in chemical engineering from the University of Pennsylvania and a Juris Doctor with honors from Rutgers University School of Law.
Timothy C. Crew was appointed chief executive officer (CEO) in January 2018, having served most recently as CEO of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. He was also appointed to the Lannett Company board of directors. Previously, Tim worked for eight years at Teva Pharmaceuticals, where he served as senior vice president and commercial operating officer of the North American Generics division, the world’s largest generic operation with multiple billions of dollars of annual sales. Before that, Tim was Teva’s vice president, Alliances and Business Development. From 2001 to 2004, Tim was executive vice president, North America, for Dr. Reddy’s Laboratories.
Tim began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development, and strategic planning. Prior to his pharmaceutical roles, Tim served in the United States Army, where he rose to the rank of captain.